In cancer immunotherapy, robust and efficient activation of cytotoxic CD8+ T cell immune responses is a promising, but challenging task. Dendritic cells (DCs) are well-known professional antigen ...

SAN ANTONIO, May 15, 2025 /PRNewswire/ -- The START Center for Cancer Research ("START"), the world's largest early-phase community-based oncology site network, today announced the dosing of the first ...

Tumor infiltrating lymphocyte (TIL) therapy for cancer treatment, illustration. During TIL therapy, T-cells (blue) that recognize tumor cells (red) are obtained from a patient.

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science ...

The initiation of T-cell–mediated antitumor immune responses requires the uptake and processing of tumor antigens by dendritic cells and their presentation on MHC-I molecules. Here we show in a ...

Tumor cells can escape T cells responses by a variety of mechanisms including the loss of the antigen presentation capacity. One of the key mechanisms of tumor rejection is the induction of anti-tumor ...

The team developed mouse models of lung cancer with different, well-defined patterns of cancer-associated antigen expression to study how these antigens affect T-cell responses. They created “clonal” ...

Tumor-infiltrating lymphocytes (TIL) were presumed to be enriched for T cells recognizing specific tumor-rejection antigens and as originally envisioned by Rosenberg et al, 9 could potentially be ...

The antigen-presentation gene expression signature and tumor immunogenicity landscape of 32 cancer types from The Cancer Genome Atlas (TCGA) project are provided. TIGS exhibits improved performance in ...

Keywords: toll-like receptors, immuno-oncology, anti-cancer immunity, tumor rejection, immunotherapy. Citation: Urban-Wojciuk Z, Khan MM, Oyler BL, Fåhraeus R, Marek-Trzonkowska N, Nita-Lazar A, Hupp ...